Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Completed
National Cancer Institute (NCI)
Phase 2
1994-09-01
Phase II trial to study the effectiveness of homoharringtonine and interferon alfa in
treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy use different
ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may
interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may
kill more cancer cells.
Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Completed
National Cancer Institute (NCI)
Phase 2
1998-03-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining biological therapy with chemotherapy may kill more
cancer cells.
PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and
homoharringtonine and biological therapy with interferon alfa in treating patients with
chronic phase chronic myelogenous leukemia.
Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Completed
M.D. Anderson Cancer Center
Phase 2
1998-03-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining biological therapy with chemotherapy may kill more
cancer cells.
PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and
homoharringtonine and biological therapy with interferon alfa in treating patients with
chronic phase chronic myelogenous leukemia.
Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase
Completed
National Cancer Institute (NCI)
Phase 2
1999-03-01
Phase II trial to study the effectiveness of homoharringtonine plus low-dose cytarabine in
treating patients who have newly diagnosed chronic phase chronic myelogenous leukemia. Drugs
used in chemotherapy use different ways to stop cancer cells from dividing so they stop
growing or die. Combining more than one drug may kill more cancer cells.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
